| Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy AC Palmer, PK Sorger Cell 171 (7), 1678-1691. e13, 2017 | 577 | 2017 |
| Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors S Goel, Q Wang, AC Watt, SM Tolaney, DA Dillon, W Li, S Ramm, ... Cancer cell 29 (3), 255-269, 2016 | 434 | 2016 |
| Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance AC Palmer, R Kishony Nature Reviews Genetics 14 (4), 243-248, 2013 | 335 | 2013 |
| Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors AC Palmer, JB Egan, KE Shearwin Transcription 2 (1), 9-14, 2011 | 201 | 2011 |
| Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes AC Palmer, E Toprak, M Baym, S Kim, A Veres, S Bershtein, R Kishony Nature communications 6 (1), 7385, 2015 | 158 | 2015 |
| Opposing effects of target overexpression reveal drug mechanisms AC Palmer, R Kishony Nature Communications 5, 2014 | 147 | 2014 |
| Independent drug action in combination therapy: implications for precision oncology D Plana, AC Palmer, PK Sorger Cancer discovery 12 (3), 606-624, 2022 | 133 | 2022 |
| A Mathematical Model for Transcriptional Interference by RNA Polymerase Traffic in Escherichia coli K Sneppen, IB Dodd, KE Shearwin, AC Palmer, RA Schubert, BP Callen, ... Journal of Molecular Biology 346 (2), 399-409, 2005 | 132 | 2005 |
| Potent transcriptional interference by pausing of RNA polymerases over a downstream promoter AC Palmer, A Ahlgren-Berg, JB Egan, IB Dodd, KE Shearwin Molecular Cell 34 (5), 545-555, 2009 | 103 | 2009 |
| A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity AC Palmer, C Chidley, PK Sorger Elife 8, e50036, 2019 | 99 | 2019 |
| Chemical decay of an antibiotic inverts selection for resistance AC Palmer, E Angelino, R Kishony Nature Chemical Biology 6 (2), 105-107, 2010 | 95 | 2010 |
| DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020 | 79 | 2020 |
| Drug independence and the curability of cancer by combination chemotherapy AE Pomeroy, EV Schmidt, PK Sorger, AC Palmer Trends in cancer 8 (11), 915-929, 2022 | 67 | 2022 |
| Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors AC Palmer, B Izar, H Hwangbo, PK Sorger Clinical Cancer Research 28 (2), 368-377, 2022 | 64* | 2022 |
| Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming H Wang, RP Sheehan, AC Palmer, RA Everley, SA Boswell, N Ron-Harel, ... Cell systems 8 (5), 412-426. e7, 2019 | 60 | 2019 |
| Pervasive selection for and against antibiotic resistance in inhomogeneous multistress environments R Chait, AC Palmer, I Yelin, R Kishony Nature communications 7 (1), 10333, 2016 | 54 | 2016 |
| Nonoptimal gene expression creates latent potential for antibiotic resistance AC Palmer, R Chait, R Kishony Molecular biology and evolution 35 (11), 2669-2684, 2018 | 50 | 2018 |
| Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas R Koch, AL Christie, JL Crombie, AC Palmer, D Plana, K Shigemori, ... Blood, The Journal of the American Society of Hematology 133 (6), 566-575, 2019 | 49 | 2019 |
| The role of repressor kinetics in relief of transcriptional interference between convergent promoters N Hao, AC Palmer, A Ahlgren-Berg, KE Shearwin, IB Dodd Nucleic Acids Research 44 (14), 6625-6638, 2016 | 31 | 2016 |
| Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast cancer cells SS Chopra, A Jenney, A Palmer, M Niepel, M Chung, C Mills, ... Cell systems 10 (1), 66-81. e11, 2020 | 29 | 2020 |
Peter K. SorgerHarvard Medical School在 hms.harvard.edu 的电子邮件经过验证
